TherapySelector vs myFibroScan

TherapySelector supports you as a physician to easily and quickly choose a data-based, person-centered treatment for hypertension and hepatitis C for and with your patient during consultation hours. The app shows in a single glance information about the effectiveness of medication based on the disease remission (systolic blood pressure lower than 140 mmHg for hypertension and viral clearance in hepatitis C), the likelihood of adverse events, cost and patient group size. This overview allows you to easily and quickly decide on the best person-centered treatment method for your patient, based on study data. How does TherapySelector work? First you enter the requested characteristics of your patient by answering 4 simple questions about etiology, disease stage, previous treatments and comorbidities. Based on this, a profile of the patient is determined. The app then shows an overview of all registered treatments for that specific patient profile, based on frequently updated study results. For each therapy you find information about effectiveness, possible adverse events and costs. TherapySelector currently provides the following features: • Determination of patient profiles based on four simple questions about the patient. • Probability of "success" of all registered medication (combinations) for hypertension and hepatitis C, together with the probability of adverse events associated with the patient profile, based on individual patient data from key clinical scientific studies. • For hypertension: overview of therapy options with Thiazide diuretics (THZ), Calcium Channel Blockers (CCA), ACE inhibitors (ACEi) or Angiotensin Receptor Blockers (ARB). Information on monotherapy with dose increase (Titrate), and results of stepwise addition of medication (Titrate & Add). • Detail information, including information about dosage (of the therapy regime) and the cost of a specific treatment. • Availability in both English and Dutch. TherapySelector is intended to provide physicians and patients person-centered information to support them in choosing the most appropriate treatment. In doing so, the app complements guidelines that are based on the ‘average’ patient. The TherapySelector app can be used without creating an account. Developed with (academic) medical centers and research institutes TherapySelector is developed by TherapySelector in collaboration with physicians and scientists associated with universities and leading academic medical centers such as the Erasmus MC, LUMC and MUMC+. The data in the app has been authorized by specialists from Dutch scientific associations. The results are calculated using anonymous patient data from scientific studies of published randomized controlled trials, other phase 2 & 3 studies and prospective real-life studies around the world (high quality research). Research groups and sponsors make their data available for this purpose. About TherapySelector TherapySelector B.V. is a social enterprise. Our mission is to improve health care globally by enriching it with person-centered treatment information based on the most recent data from scientific studies. It is not our goal to make profit. With the TherapySelector app, we facilitate doctors with person-centered care to achieve health gains for their patients. Additionally, we want to aid in controlling the rising costs of healthcare for the public, e.g. by preventing over- and under-treatment. Follow us on LinkedIn (https://www.linkedin.com/company/therapyselector) or visit www.therapyselector.com.

FibroScan® is the non-invasive gold standard solution for comprehensive management of liver health. FibroScan® is powered by three unique, patented and validated biomarkers, LSM by VCTE™ (Liver Stiffness Measurement) and CAP™ (Controlled Attenuation Parameter) that benefit from a worldwide clinical evidence with over 5300+ peer-reviewed publications and 180+ international guidelines. myFibroScan app is your everyday FibroScan® companion to access Interpretation Guide and FibroScan® based scores in an easy, fast and intuitive way : The Interpretation Guide utilizes data from clinical studies to assist providers in interpreting FibroScan® examination results. Scores enhance FibroScan® liver disease assessment with biological markers. Scores are presented as educational services intended for licensed healthcare professionals. While the scores are about specific medical and healthcare issues, they are not a substitute for/or replacement of personalized medical advice and are not intended to be used as the sole basis for making individualized medical or health-related decisions. • Fast is an aid to identify at risk MASH patients defined as MASH + NAS≥4 + F≥2. Good to excellent performance in cohorts from different clinical settings (MASLD tertiary care unit, screening, bariatric surgery) and geographical origins (USA, Europe, Asia). Several publications advocate the use of Fast. • Agile 3+ is an aid to identify MASLD patients with advanced fibrosis by combining LSM by VCTE™ and routine clinical parameters to reduce the need for liver biopsy. High clinical performances are demonstrated in large external validation cohorts from different geographical origins. • Agile 4 is an aid to early identify MASLD patients with cirrhosis by combining LSM by VCTE™ and routine clinical parameters. It can help the physicians to manage the disease to prevent liver-related complications such as hepatocellular carcinoma. High clinical performances are demonstrated in large external validation cohorts from different geographical origin. MASH Treatment Eligibility Tool to eliminate the Guesswork. This patient management tool embeds treatment recommendations based on the patient’s FibroScan® results and the latest AASLD Guidance.